Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
No high-quality clinical trials have specifically investigated microdosing as a therapeutic strategy
The new drugs were originally intended to be treatments for diabetics, but the trials noticed the large and sustained weight loss amongst participants
What Happens to Cardiovascular Benefits
Certain medicines, such as valproate
My Approach When Prescribing Here's my general framework not a rigid protocol, but a starting point for the conversation: I Tend to Start with Semaglutide When The patient has established cardiovascular disease (because of the SELECT trial data) Insurance covers semaglutide but not tirzepatide The patient has MASH/fatty liver disease Cost is the primary concern and semaglutide is more accessible I Tend to Start with Tirzepatide When Maximum weight loss is the primary goal The patient has type 2 diabetes (tirzepatide shows greater A1C reduction roughly 2.02.5% vs 1.02.0% for semaglutide) The patient has tried semaglutide with insufficient results Insurance covers both options equally Regardless of which medication we choose, I always emphasize that GLP-1 therapy is most effective when combined with nutritional counseling, physical activity, and behavioral support
